Organization | American Academy of Neurology

American Academy of Neurology Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Minneapolis MN United States (1948)

Organization Overview

First Clinical Trial

2009

NCT01054599

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

American Academy of Neurology

Active Ingredients

Drugs in Phase 4 Trials (3)

dopamine (intropin) (1 trial)

droxidopa (northera) (1 trial)

rimabotulinumtoxinB (Myobloc) (1 trial)

Drugs in Phase 2 Trials (7)

choline (1 trial)

niacin (1 trial)

omega-3 fatty acids (omacor) (1 trial)

pantothenic acid (1 trial)

riboflavin (1 trial)

uridine monophosphate (1 trial)

vitamin a (1 trial)

Drugs in Other Trials (1)

memantine (namenda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Cognitive Dysfunction (Phase 2)

Dystonia (Phase 4)

Dystonic Disorders (Phase 4)

Parkinson Disease (Phase 4)

Torticollis (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial APIs: 11